Final-Program-ATS-2023-AP.vp

296

TUESDAY • MAY 23

103 Physiological Benefits of Pulmonary Rehabilitation in Patients Preparing for Lung Transplantation/ D.R. Nunley, Columbus, OH 104 Acute Exacerbation of ILD Associated With Improved Lung Transplant Survival Compared to Other Inpatient ILD Transplants/ D.M. Guidot, Durham, NC 105 A Comparison of Combined Double Lung-liver Transplant and Double Lung Transplant in Adult Cystic Fibrosis Patients/ A. Ramirez, Shreveport, LA 106 Single Lung Transplant in Patients With Hypersensitivity Pneumonitis and Severe Secondary Pulmonary Hypertension/ B.H. Lashari, Philadelphia, PA 107 Association Between Pre-transplant Emphysema Characteristics and Post-transplant Native Lung Hyperinflation in COPD Patients Following Single Lung Transplantation/ B.H. Lashari, Philadelphia, PA 108 Impact of Pre-transplant Lung Function and Radiographic Abnormality on Post Lung Transplant Respiratory Failure and ICU Length of Stay in Patients With COPD Receiving Single Lung Transplant/ B.H. Lashari, Philadelphia, PA 109 Short Term Outcomes of Patient With COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) Bridged to Lung Transplant From Advanced Life Support/ A. Khan, Los Angeles, CA 110 Early Outcomes Following ECMO Bridged Lung Transplant in Patients With COVID-19 ARDS/ C. Tanabe, Houston, TX 111 Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation: 5-year Outcomes From a High-volume Single Center/ J. Daar, Philadelphia, PA 112 Post-operative Delirium Is Associated With Increased Mortality and Hospital Discharge Destination in Lung Transplant Recipients/ A.G. Dragnich, Nashville, TN 113 Renal Function After Everolimus and Reduced Calcineurin Inhibitor in Immune Suppression of Lung Transplant Patients: A Meta-Analysis of Randomized Controlled Trials/ A. Al-Akhras, Irbid, Jordan 114 An Emulated Multicenter Cluster-randomized Trial to Estimate the Impact of Basiliximab Induction Therapy on Acute Cellular Rejection in Lung Transplant Recipients/ J.G. Rim, Durham, NC 115 Particle Flow Rate From Exhaled Breath Correlates With Primary Graft Dysfunction Following Lung Transplantation/ G. Hirdman, Lund, Sweden 116 Lower Airway Microbial Signatures Associated With Primary Graft Dysfunction in Lung Transplantation/ T. Malik, New York, NY

816 Comparative Effectiveness of Dupilumab and Mepolizumab in Eosinophilic Asthma/ A. Akenroye, Boston, MA 817 Long-term Effectiveness of Nucala (4 Years) in Patients With Asthma: A Real-world Database Analysis/ A. Stach-Klysh, Research Triangle Park, NC 818 Breaking Thresholds to Improve Screening Tools for Obstructive Lung Disease/ A.T. Moffett, Philadelphia, PA 819 Evaluation of an Implementation Package to Deliver the COPD CARE Service/ E. Portillo, Madison, WI 820 A Model to Improve COPD Care at a Regional Medical Center/ K. Manzoor, Norwell, MA 821 “I’d Be Looking for Another Doctor” - a Mixed Methods Analysis of Patients’ Attitudes Towards Oxygen Discontinuation/ L.C. Feemster, Seattle, WA 822 Exacerbations and Real-world Outcomes (EROS) Among Patients With COPD Receiving Single Inhaler Triple Therapy of Budesonide/glycopyrrolate/formoterol Fumarate/ M. Pollack, Wilmington, DE 823 Real World Evidence: Severe Asthma Questionnaire (SAQ) and Asthma Control Questionnaire (ACQ) As Early Predictors of Biologic Response in Severe Asthma/ J.W. Lanario, Plymouth, United Kingdom 824 A National Partnership With the COPD Foundation to Implement the COPD Virtual Medication Reconciliation and Education: COPD V-M(ED) Pilot - An Interim Analysis/ S.E. Gray, Chicago, IL

CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

C103 MOVING THE NEEDLE FORWARD IN LUNG TRANSPLANTATION 2:15 p.m. - 4:15 p.m.

Marriott Marquis Washington Marquis Ballroom, Salons 1-2 (Level M2)

Poster Viewing

2:15-3:00 3:00-4:15

Discussion

Chairing: D.F. Dilling, MD, Maywood, IL R. Jablonski, MD, Chicago, IL M.B. Keller, MD, Baltimore, MD 101 The Impact of Race-specific Reference Equations on the Lung Allocation Score Among Patients Listed for Lung Transplant/ J.H. Brems, Baltimore, MD 102 Cell-free DNA Tissue Sources in Patients With Advanced Lung Diseases/ S. Balasubramanian, Bethesda, MD

ATS 2023 • Washington, DC